Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Aids 2022 preview – Gilead shoots for an HIV cure
But progress – or lack thereof – with lenacapavir is a more immediate concern.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Vaccine developers move to stay ahead of Covid-19 variants
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
